Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.

被引：0
|
作者：
Myers, Andrea P.
Filiaci, Virginia L.
Zhang, Yuping
Pearl, Michael
Behbakht, Kian
Makker, Vicky
Hanjani, Parviz
Zweizig, Susan
Burke, James J.
Downey, Gordon
Leslie, Kimberly K.
Birrer, Michael J.
Fleming, Gini F.
机构：
[1] Novartis Inst Biomed Res, Cambridge, MA USA
[2] NRG Oncol, Buffalo, NY USA
[3] GOG Fdn Inc SDMC, Buffalo, NY USA
[4] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA
[5] Univ Hosp Stony Brook, New York, NY USA
[6] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[7] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[8] Weill Cornell Med Coll, New York, NY USA
[9] Abington Memor Hosp, Gladwyne, PA USA
[10] Univ Massachusetts Memor Hlth Care, Worcester, MA USA
[11] Mercer Univ, Sch Med, Savannah, GA USA
[12] Gynecol Oncol West Michigan, Grand Rapids, MI USA
[13] Massachusetts Gen Hosp, Dana Farber Canc Ctr, Boston, MA 02114 USA
[14] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.5592
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5592
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase II study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-0231D).
    Hyman, David Michael
    Sill, Michael
    Cho, Jonathan K.
    Lankes, Heather A.
    Piekarz, Richard
    Hensley, Martee Leigh
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [22] Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study
    Burger, Robert A.
    Deng, Wei
    Makker, Vicky
    Collins, Yvonne
    Gray, Heidi
    Debernardo, Robert
    Martin, Lainie P.
    Aghajanian, Carol
    GYNECOLOGIC ONCOLOGY, 2018, 150 (03) : 466 - 470
  • [23] A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)
    Chan, John K.
    Brady, William
    Monk, Bradley J.
    Brown, Jubilee
    Shahin, Mark S.
    Rose, Peter G.
    Kim, Jae-Hoon
    Secord, Angeles Alvarez
    Walker, Joan L.
    Gershenson, David M.
    GYNECOLOGIC ONCOLOGY, 2018, 150 (02) : 247 - 252
  • [24] A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus: An NRG/Gynecologic Oncology Group study.
    McCourt, Carolyn K.
    Powell, Matthew
    Tenney, Meaghan Elizabeth
    Kushner, David M.
    Rotmensch, Jacob
    Kendrick, James Erasmus
    Warshal, David Philip
    Deng, Wei
    Saltzman, Joel N.
    Dizon, Don S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study
    Phippen, N. T.
    Secord, A. A.
    Wolf, S.
    Samsa, G.
    Davidson, B.
    Abernethy, A. P.
    Cella, D.
    Havrilesky, L. J.
    Burger, R. A.
    Monk, B. J.
    Leath, C. A., III
    GYNECOLOGIC ONCOLOGY, 2017, 147 (01) : 98 - 103
  • [26] The value of TOP2A as a target for anthracycline-based chemotherapy in advanced endometrial carcinoma (EC): NRG Oncology/Gynecology Oncology Group study.
    Grushko, Tatyana A.
    Filiaci, Virginia L.
    Montag, Anthony G.
    Apushkin, Marsha A.
    Marzullo, Brandon
    Monovich, Laura
    Ramirez, Nilsa C.
    Birrer, Michael J.
    Olopade, Olufunmilayo I.
    Fleming, Gini F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] Preoperative chemoradiation for advanced vulvar cancer: A phase II study of the gynecologic oncology group
    Moore, DH
    Thomas, GM
    Montana, GS
    Saxer, A
    Gallup, DG
    Olt, G
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 42 (01): : 79 - 85
  • [28] Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study
    Aghajanian, Carol
    Sill, Michael W.
    Darcy, Kathleen M.
    Greer, Benjamin
    McMeekin, D. Scott
    Rose, Peter G.
    Rotmensch, Jacob
    Barnes, Mack N.
    Hanjani, Parviz
    Leslie, Kimberly K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) : 2259 - 2265
  • [29] A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: A gynecologic oncology group study
    Rose, PG
    Brunetto, VL
    VanLe, L
    Bell, J
    Walker, JL
    Lee, RB
    GYNECOLOGIC ONCOLOGY, 2000, 78 (02) : 212 - 216
  • [30] Final overall survival (OS) analysis of an international randomized trial evaluating bevacizumab (BEV) in the primary treatment of advanced ovarian cancer: A NRG oncology/Gynecologic Oncology Group (GOG) study
    Burger, Robert Allen
    Enserro, Danielle
    Tewari, Krishnansu Sujata
    Brady, Mark F.
    Bookman, Michael A.
    Fleming, Gini F.
    Huang, Helen Q.
    Homesley, Howard D.
    Fowler, Jeffrey
    Boente, Matthew
    Randall, Leslie M.
    Chan, John K.
    Ferris, James Stuart
    DiSaia, Philip J.
    Copeland, Larry J.
    Mannel, Robert S.
    Birrer, Michael J.
    Monk, Bradley J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345